News Messenger
  • News
    • Local
    • Sports
    • School
    • State News
    • National News
  • Obituaries
  • Opinions
  • Spiritual
    • Parabola
    • Transcendental Meditation
    • The Episcopal Diocese of Virginia
    • Southern Baptist
  • Legals
  • eEdition
  • Classifieds
  • Contact Us
  • My Account
  • Login
Subscribe For $2.50/Month
No Result
View All Result
  • News
    • Local
    • Sports
    • School
    • State News
    • National News
  • Obituaries
  • Opinions
  • Spiritual
    • Parabola
    • Transcendental Meditation
    • The Episcopal Diocese of Virginia
    • Southern Baptist
  • Legals
  • eEdition
  • Classifieds
  • Contact Us
  • My Account
  • Login
No Result
View All Result
News Messenger
No Result
View All Result
  • National News
  • VA State News
  • WV State News
  • Contact Us
  • Submit Content
  • Subscribe
Home Local Stories

Fralin biotech spin-out raises nearly $1 million for cancer stem cell research

January 7, 2022
in Local Stories
24
VIEWS
Share on FacebookShare on Twitter
Samy Lamouille, assistant professor at the Fralin Biomedical Research Institute at VTC, is chief executive officer of Acomhal Research Inc., a biotech spinoff company that recently received $305,000 in funding to continue its pursuit of a therapeutic for drug-resistant and metastatic cancers. Photo courtesy of Matt Chittum for Virginia Tech.

With a wave of new grants and investments, a cancer stem cell research company founded by Fralin Biomedical Research Institute at VTC scientists is nearing a million dollars in total funding toward development of a new therapeutic to fight drug-resistant cancers. 

Acomhal Research Inc. was recently awarded $305,000, including $150,000 from the Virginia Tech Carilion Seed Fund, $100,000 from the Virginia Innovation Partnership Corporation (VIPC) GAP Funds Program, and $55,000 from the CommonWealth Angels investment group. Those funds follow $625,000 the company received in Small Business Technology Transfer (STTR) grants over the previous four years. The VIPC was formerly the Center for Innovative Technology.

“We need to rethink how we treat cancer. Resistance and recurrence result from distinct mechanisms to the original tumor,” said Samy Lamouille, Acomhal’s co-founder and chief executive officer and an assistant professor at the Fralin Biomedical Research Institute. “Having spent over 20 years in the cancer research and drug development field, I am very excited about the direction Acomhal is taking in development of our novel therapeutic approach.”

Cancer is the second-leading cause of death in the United States with more than half a million deaths per year. Many forms of cancer present serious treatment challenges, but a population of “cancer stem cells” within tumors is especially resistant to chemotherapy and radiation. Even a small number of cancer stem cells can rapidly fuel the growth of new tumors if they aren’t eradicated.

Acomhal is developing a novel peptide drug that targets and kills cancer stem cells, preventing them from seeding new tumors. It works by competing with a protein, connexin43, for binding sites on cancer stem cells’ microtubules, hollow protein pipes that cells need to transport proteins, grow, and move.

Lamouille’s research also has shown that when connexin43 is unable to bind to microtubules, metastatic cancer cells become less invasive, further limiting the ability of cancer to spread in addition to cancer stem cell loss.

“With the help of local investors in Virginia, and through continued collaborations at Virginia Tech and Fralin Biomedical Research Institute, our goal is now to pursue human clinical trials and directly impact patients’ lives in our fight against this devastating disease” Lamouille said.

 

Previous Post

Montgomery Museum presents quilting work of Jenna Pynn

Next Post

Food City Recognizes Radford associate Angel Grubbs for outstanding volunteerism

Next Post

Food City Recognizes Radford associate Angel Grubbs for outstanding volunteerism

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Join Our Newsletter

  • Login
  • Sign Up
  • Cart
No Result
View All Result
  • News
    • Local
    • Sports
    • School
    • State News
    • National News
  • Obituaries
  • Opinions
  • Spiritual
    • Parabola
    • Transcendental Meditation
    • The Episcopal Diocese of Virginia
    • Southern Baptist
  • Legals
  • eEdition
  • Classifieds
  • Contact Us
  • My Account
  • Login

© 2020 Mountain Media, LLC.

Welcome Back!

Login to your account below

Forgotten Password? Sign Up

Create New Account!

Fill the forms below to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In

Forgot your password?

Lost your password? Please enter your email address. You will receive mail with link to set new password.

Back to login